8-K: SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SeaStar Medical announced its financial results for the three months and year ended December 31, 2024, along with business updates, highlighting FDA approval for QUELIMMUNE and progress in the NEUTRALIZE AKI trial.

Summary

• SeaStar Medical announced financial results for Q4 and full year 2024.
• Net revenue for 2024 was $0.1 million, compared to no revenue in 2023, due to the launch of QUELIMMUNE therapy.
• Research and development expenses increased to $9.1 million in 2024 from $6.0 million in 2023, driven by clinical trial and personnel expenses.
• General and administrative expenses rose to $8.9 million in 2024 from $8.2 million in 2023, due to increased headcount and legal expenses.
• Net loss for 2024 was $24.8 million, compared to a net loss of $26.2 million in 2023.
• The company had $1.8 million in cash, cash equivalents, and short-term investments as of December 31, 2024, not including $6 million from a registered direct financing completed in February 2025.
• The company received FDA approval for QUELIMMUNE therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
• The NEUTRALIZE AKI pivotal trial has enrolled 94 of the anticipated 200 patients.
• The company was awarded its fourth Breakthrough Device Designation.
• The National Kidney Foundation awarded SeaStar Medical its 2025 Corporate Innovator Award.
• The company secured approximately $31 million in capital and reduced debt and liabilities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, it also achieved key milestones such as FDA approval and progress in clinical trials. The secured capital and reduction in debt are also positive signs.

Positives

• FDA approval and commercial launch of QUELIMMUNE therapy.
• Progress in the NEUTRALIZE AKI pivotal trial with 94 patients enrolled.
• Awarded fourth Breakthrough Device Designation.
• Awarded the National Kidney Foundation's 2025 Corporate Innovator Award.
• Secured approximately $31 million in capital and reduced debt and liabilities.
• Net revenue increased to $0.1 million in 2024 from no revenue in 2023.
• FDA approved a feasibility study for its SCD therapy as a treatment for cardiorenal syndrome as a bridge to left ventricular assist device.
• Expanded the proprietary protection for the SCD through the award of U.S. Patent No. 11,866,730 and Canadian Patent No. 2814586.

Negatives

• Net loss for 2024 was $24.8 million.
• Cash, cash equivalents and short term investments at December 31 2024, were $1.8 million.

Risks

• The company may not be able to obtain regulatory approval of its SCD product candidates.
• The company may not be able to raise sufficient capital to fund its operations.
• Third-party suppliers and manufacturers may not be able to fully and timely meet their obligations.
• The company may face product liability or regulatory lawsuits or proceedings.
• The company may be unable to secure or protect its intellectual property.

Future Outlook

The company anticipates a transformational year in 2025, driven by the commercial launch of QUELIMMUNE and continued progress in the NEUTRALIZE AKI pivotal trial.

Management Comments

• 'Our significant accomplishment in 2024 position us well for a transformational year in 2025,' said Eric Schlorff, SeaStar Medical CEO.
• Mr. Schlorff continued, 'And I am pleased to report that our momentum has continued this year.'

Industry Context

SeaStar Medical is operating in the critical care space, focusing on treatments for organ failure, particularly acute kidney injury (AKI). The company's QUELIMMUNE therapy addresses an ultra-rare condition in pediatric patients, while the SCD therapy targets a broader adult AKI population. The Breakthrough Device Designation and NIH grant highlight the potential for the SCD therapy in addressing unmet needs in chronic systemic inflammation and heart failure.

Comparison to Industry Standards

• It's difficult to directly compare SeaStar Medical to industry giants due to its focus on niche markets within critical care.
• Companies like Baxter and Fresenius Medical Care offer products for renal replacement therapy, but SeaStar's SCD therapy uses a unique immunomodulation approach.
• The $3.6 million NIH grant for SCD therapy research is a positive sign, as NIH grants are highly competitive and awarded to projects with high potential impact.
• The Breakthrough Device Designation could lead to faster regulatory pathways and preferable reimbursement, similar to how orphan drug designations benefit companies targeting rare diseases.

Stakeholder Impact

• Shareholders: The financial results and business updates provide information for investment decisions.
• Patients: The QUELIMMUNE therapy offers a treatment option for pediatric patients with AKI due to sepsis.
• Employees: The company's progress and financial stability impact job security and growth opportunities.
• Customers: Hospitals and medical centers can adopt the QUELIMMUNE therapy for their patients.
• Researchers: The NIH grant supports further research and development of the SCD therapy.

Next Steps

• Continue enrollment in the NEUTRALIZE AKI pivotal trial.
• Expand commercialization of QUELIMMUNE therapy.
• Pursue regulatory approval for SCD therapy.
• Advance clinical trial for SCD therapy as a bridge to left ventricular assist device implantation.

Key Dates

Keywords

SeaStar Medical, QUELIMMUNE, NEUTRALIZE AKI, Acute Kidney Injury, Sepsis, SCD Therapy, Financial Results, Breakthrough Device Designation, Clinical Trial, FDA Approval